Show simple item record

dc.contributor.authorPande, Sandhya
dc.contributor.authorBrowne, Gillian
dc.contributor.authorPadmanabhan, Srivatsan
dc.contributor.authorZaidi, Kaleem
dc.contributor.authorLian, Jane B.
dc.contributor.authorVan Wijnen, Andre J.
dc.contributor.authorStein, Janet L.
dc.contributor.authorStein, Gary S.
dc.date2022-08-11T08:08:31.000
dc.date.accessioned2022-08-23T15:57:47Z
dc.date.available2022-08-23T15:57:47Z
dc.date.issued2013-08-01
dc.date.submitted2015-01-15
dc.identifier.citationJ Cell Physiol. 2013 Aug;228(8):1784-92. doi: 10.1002/jcp.24339. <a href="http://dx.doi.org/10.1002/jcp.24339">Link to article on publisher's site</a>
dc.identifier.issn0021-9541 (Linking)
dc.identifier.doi10.1002/jcp.24339
dc.identifier.pmid23389849
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30282
dc.description.abstractThe serine/threonine kinase Akt/PKB promotes cancer cell growth and invasion through several downstream targets. Identification of novel substrates may provide new avenues for therapeutic intervention. Our study shows that Akt phosphorylates the cancer-related transcription factor Runx2 resulting in stimulated DNA binding of the purified recombinant protein in vitro. Pharmacological inhibition of the PI3K/Akt pathway in breast cancer cells reduces DNA-binding activity of Runx2 with concomitant reduction in the expression of metastasis-related Runx2 target genes. Akt phosphorylates Runx2 at three critical residues within the runt DNA-binding domain to enhance its in vivo genomic interactions with a target gene promoter, MMP13. Mutation of these three phosphorylation sites reduces Runx2 DNA-binding activity. However, Akt signaling does not appear to interefere with CBFbeta-Runx2 interactions. Consequently, expression of multiple metastasis-related genes is decreased and Runx2-mediated cell invasion is supressed. Thus, our work identifies Runx2 as a novel and important downstream mediator of the PI3K/Akt pathway that is linked to metastatic properties of breast cancer cells.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23389849&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685436/
dc.subjectAnimals
dc.subjectBinding Sites
dc.subjectBreast Neoplasms
dc.subjectCell Line, Tumor
dc.subjectCore Binding Factor Alpha 1 Subunit
dc.subjectCore Binding Factor beta Subunit
dc.subjectDNA, Neoplasm
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMammary Neoplasms, Experimental
dc.subjectMice
dc.subjectMice, Transgenic
dc.subjectMutagenesis, Site-Directed
dc.subjectNeoplasm Invasiveness
dc.subjectPhosphatidylinositol 3-Kinases
dc.subjectPhosphorylation
dc.subjectProto-Oncogene Proteins c-akt
dc.subjectSignal Transduction
dc.subjectCancer Biology
dc.subjectCell Biology
dc.subjectCellular and Molecular Physiology
dc.subjectNeoplasms
dc.subjectOncology
dc.titleOncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells
dc.typeJournal Article
dc.source.journaltitleJournal of cellular physiology
dc.source.volume228
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/535
dc.identifier.contextkey6532262
html.description.abstract<p>The serine/threonine kinase Akt/PKB promotes cancer cell growth and invasion through several downstream targets. Identification of novel substrates may provide new avenues for therapeutic intervention. Our study shows that Akt phosphorylates the cancer-related transcription factor Runx2 resulting in stimulated DNA binding of the purified recombinant protein in vitro. Pharmacological inhibition of the PI3K/Akt pathway in breast cancer cells reduces DNA-binding activity of Runx2 with concomitant reduction in the expression of metastasis-related Runx2 target genes. Akt phosphorylates Runx2 at three critical residues within the runt DNA-binding domain to enhance its in vivo genomic interactions with a target gene promoter, MMP13. Mutation of these three phosphorylation sites reduces Runx2 DNA-binding activity. However, Akt signaling does not appear to interefere with CBFbeta-Runx2 interactions. Consequently, expression of multiple metastasis-related genes is decreased and Runx2-mediated cell invasion is supressed. Thus, our work identifies Runx2 as a novel and important downstream mediator of the PI3K/Akt pathway that is linked to metastatic properties of breast cancer cells.</p>
dc.identifier.submissionpathfaculty_pubs/535
dc.contributor.departmentCancer Center
dc.contributor.departmentDepartment of Cell Biology
dc.source.pages1784-92


This item appears in the following Collection(s)

Show simple item record